Washington Trust Advisors Inc. Lowers Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Washington Trust Advisors Inc. decreased its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 7.1% during the first quarter, according to the company in its most recent disclosure with the SEC. The fund owned 17,913 shares of the medical equipment provider's stock after selling 1,374 shares during the quarter. Washington Trust Advisors Inc.'s holdings in Intuitive Surgical were worth $8,872,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Ameritas Advisory Services LLC grew its holdings in shares of Intuitive Surgical by 5.9% in the first quarter. Ameritas Advisory Services LLC now owns 1,724 shares of the medical equipment provider's stock worth $878,000 after purchasing an additional 96 shares during the last quarter. Amalgamated Bank grew its stake in Intuitive Surgical by 2.0% in the 1st quarter. Amalgamated Bank now owns 79,770 shares of the medical equipment provider's stock worth $39,508,000 after acquiring an additional 1,599 shares in the last quarter. Crown Wealth Group LLC increased its position in shares of Intuitive Surgical by 4.8% during the first quarter. Crown Wealth Group LLC now owns 440 shares of the medical equipment provider's stock worth $218,000 after acquiring an additional 20 shares during the period. Avidian Wealth Enterprises LLC raised its stake in shares of Intuitive Surgical by 9.7% during the first quarter. Avidian Wealth Enterprises LLC now owns 988 shares of the medical equipment provider's stock valued at $489,000 after acquiring an additional 87 shares in the last quarter. Finally, Naviter Wealth LLC raised its stake in shares of Intuitive Surgical by 1.2% during the first quarter. Naviter Wealth LLC now owns 3,638 shares of the medical equipment provider's stock valued at $1,789,000 after acquiring an additional 43 shares in the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Intuitive Surgical

In related news, Director Jami K. Nachtsheim sold 2,400 shares of Intuitive Surgical stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $520.00, for a total value of $1,248,000.00. Following the completion of the sale, the director directly owned 6,371 shares in the company, valued at $3,312,920. This trade represents a 27.36% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Gary Loeb sold 1,700 shares of the company's stock in a transaction that occurred on Friday, April 25th. The shares were sold at an average price of $513.18, for a total transaction of $872,406.00. Following the transaction, the executive vice president owned 2,245 shares in the company, valued at $1,152,089.10. The trade was a 43.09% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 4,998 shares of company stock worth $2,611,577. 0.70% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on ISRG shares. Barclays dropped their price objective on Intuitive Surgical from $684.00 to $635.00 and set an "overweight" rating on the stock in a research note on Thursday, April 24th. Erste Group Bank raised Intuitive Surgical from a "hold" rating to a "buy" rating in a research report on Thursday, June 5th. Piper Sandler decreased their price objective on Intuitive Surgical from $670.00 to $575.00 and set an "overweight" rating for the company in a report on Wednesday, April 23rd. Evercore ISI lowered their price objective on shares of Intuitive Surgical from $510.00 to $470.00 and set an "in-line" rating for the company in a research note on Wednesday, April 23rd. Finally, Truist Financial cut their target price on shares of Intuitive Surgical from $605.00 to $590.00 and set a "buy" rating on the stock in a research report on Wednesday, April 23rd. One research analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $588.95.

Intuitive Surgical Trading Up 0.6%

Shares of ISRG traded up $3.14 during midday trading on Thursday, hitting $543.74. 704,815 shares of the company's stock traded hands, compared to its average volume of 1,667,111. The stock has a market capitalization of $194.89 billion, a price-to-earnings ratio of 79.73, a price-to-earnings-growth ratio of 5.71 and a beta of 1.64. Intuitive Surgical, Inc. has a 1 year low of $413.82 and a 1 year high of $616.00. The firm's fifty day moving average is $535.82 and its 200-day moving average is $536.76.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last released its quarterly earnings results on Tuesday, April 22nd. The medical equipment provider reported $1.81 EPS for the quarter, beating analysts' consensus estimates of $1.71 by $0.10. The company had revenue of $2.25 billion during the quarter, compared to analysts' expectations of $2.19 billion. Intuitive Surgical had a return on equity of 14.43% and a net margin of 28.41%. During the same period last year, the business posted $1.50 earnings per share. On average, equities research analysts anticipate that Intuitive Surgical, Inc. will post 6.43 EPS for the current year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.